Cargando…
Genetic testing in children with Brugada syndrome: results from a large prospective registry
FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND/INTRODUCTION: A pathogenic/likely pathogenic (P/LP) variant can be found in 20-25% of patients with Brugada syndrome (BrS) and a P/LP variant in SCN5A is associated with a worse prognosis. However, the diagnostic yield and the progn...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207434/ http://dx.doi.org/10.1093/europace/euad122.267 |
_version_ | 1785046452676853760 |
---|---|
author | Pannone, L Osey, R Gauthey, A Sorgente, A Della Rocca, D G Overeinder, I Bala, G Almorad, A Stroker, E Sieira, J La Meir, M Brugada, P Chierchia, G B Van Dooren, S De Asmundis, C |
author_facet | Pannone, L Osey, R Gauthey, A Sorgente, A Della Rocca, D G Overeinder, I Bala, G Almorad, A Stroker, E Sieira, J La Meir, M Brugada, P Chierchia, G B Van Dooren, S De Asmundis, C |
author_sort | Pannone, L |
collection | PubMed |
description | FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND/INTRODUCTION: A pathogenic/likely pathogenic (P/LP) variant can be found in 20-25% of patients with Brugada syndrome (BrS) and a P/LP variant in SCN5A is associated with a worse prognosis. However, the diagnostic yield and the prognosis of gene testing in pediatric BrS syndrome is unclear. PURPOSE: The aim of this study is to define the diagnostic yield of SCN5A gene testing with ACMG standardized variant classification in a large cohort of pediatric BrS. Furthermore, a correlation between the clinical outcomes and the genetic background of children with BrS in comparison with adult BrS is aimed. METHODS: All consecutive patients diagnosed with BrS, between 1992 and 2022 were enrolled in a prospective monocentric registry. Inclusion criteria were: 1) BrS diagnosis; 2) Genetic analysis for SCN5A gene and 3) classification of gene variants following current ACMG guidelines. Pediatric patients were defined if ≤ 12 years of age. The primary endpoint was ventricular arrhythmias (VA) occurrence, defined as documented SCD, aborted SCD, ventricular tachycardia or ventricular fibrillation or appropriate ICD intervention. RESULTS: A total of 500 BrS patients were included, 41 pediatric patients and 459 adult patients. Among children with BrS, 19 patients (46.3%) had a P/LP variant (P+) in SCN5A gene. No P/LP variants could be identified in 22 (53.7%) pediatric patients (P-). After a mean follow-up of 140.2 months, 3 children (7.3%) experienced a VA, treated with appropriate ICD shock. Inappropriate shocks occurred in 3 pediatric patients (7.3%). At survival analysis, P- pediatric patients had higher VA free survival during the follow-up, compared with P+ pediatric patients (Log-Rank p=0.021), Figure 1. There was no difference in VA free survival between pediatric and adult BrS patients both without (P-), (Log-Rank p=0.19) and with (P+) a P/LP variant (Log-Rank p=0.91), Figure 2. CONCLUSION: In a large BrS cohort, the diagnostic yield for SCN5A P/LP variants in the pediatric population is 46.3%. P+ children with BrS have a worse arrhythmic prognosis. [Figure: see text] [Figure: see text] |
format | Online Article Text |
id | pubmed-10207434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102074342023-05-25 Genetic testing in children with Brugada syndrome: results from a large prospective registry Pannone, L Osey, R Gauthey, A Sorgente, A Della Rocca, D G Overeinder, I Bala, G Almorad, A Stroker, E Sieira, J La Meir, M Brugada, P Chierchia, G B Van Dooren, S De Asmundis, C Europace 13.2 - Epidemiology, Prognosis, Outcome FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND/INTRODUCTION: A pathogenic/likely pathogenic (P/LP) variant can be found in 20-25% of patients with Brugada syndrome (BrS) and a P/LP variant in SCN5A is associated with a worse prognosis. However, the diagnostic yield and the prognosis of gene testing in pediatric BrS syndrome is unclear. PURPOSE: The aim of this study is to define the diagnostic yield of SCN5A gene testing with ACMG standardized variant classification in a large cohort of pediatric BrS. Furthermore, a correlation between the clinical outcomes and the genetic background of children with BrS in comparison with adult BrS is aimed. METHODS: All consecutive patients diagnosed with BrS, between 1992 and 2022 were enrolled in a prospective monocentric registry. Inclusion criteria were: 1) BrS diagnosis; 2) Genetic analysis for SCN5A gene and 3) classification of gene variants following current ACMG guidelines. Pediatric patients were defined if ≤ 12 years of age. The primary endpoint was ventricular arrhythmias (VA) occurrence, defined as documented SCD, aborted SCD, ventricular tachycardia or ventricular fibrillation or appropriate ICD intervention. RESULTS: A total of 500 BrS patients were included, 41 pediatric patients and 459 adult patients. Among children with BrS, 19 patients (46.3%) had a P/LP variant (P+) in SCN5A gene. No P/LP variants could be identified in 22 (53.7%) pediatric patients (P-). After a mean follow-up of 140.2 months, 3 children (7.3%) experienced a VA, treated with appropriate ICD shock. Inappropriate shocks occurred in 3 pediatric patients (7.3%). At survival analysis, P- pediatric patients had higher VA free survival during the follow-up, compared with P+ pediatric patients (Log-Rank p=0.021), Figure 1. There was no difference in VA free survival between pediatric and adult BrS patients both without (P-), (Log-Rank p=0.19) and with (P+) a P/LP variant (Log-Rank p=0.91), Figure 2. CONCLUSION: In a large BrS cohort, the diagnostic yield for SCN5A P/LP variants in the pediatric population is 46.3%. P+ children with BrS have a worse arrhythmic prognosis. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207434/ http://dx.doi.org/10.1093/europace/euad122.267 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | 13.2 - Epidemiology, Prognosis, Outcome Pannone, L Osey, R Gauthey, A Sorgente, A Della Rocca, D G Overeinder, I Bala, G Almorad, A Stroker, E Sieira, J La Meir, M Brugada, P Chierchia, G B Van Dooren, S De Asmundis, C Genetic testing in children with Brugada syndrome: results from a large prospective registry |
title | Genetic testing in children with Brugada syndrome: results from a large prospective registry |
title_full | Genetic testing in children with Brugada syndrome: results from a large prospective registry |
title_fullStr | Genetic testing in children with Brugada syndrome: results from a large prospective registry |
title_full_unstemmed | Genetic testing in children with Brugada syndrome: results from a large prospective registry |
title_short | Genetic testing in children with Brugada syndrome: results from a large prospective registry |
title_sort | genetic testing in children with brugada syndrome: results from a large prospective registry |
topic | 13.2 - Epidemiology, Prognosis, Outcome |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207434/ http://dx.doi.org/10.1093/europace/euad122.267 |
work_keys_str_mv | AT pannonel genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT oseyr genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT gautheya genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT sorgentea genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT dellaroccadg genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT overeinderi genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT balag genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT almorada genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT strokere genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT sieiraj genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT lameirm genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT brugadap genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT chierchiagb genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT vandoorens genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry AT deasmundisc genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry |